Clinical Trial Update: Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a Phase 1/2 trial evaluating weekly paclitaxel, carboplatin, and bevacizumab as first-line therapy for triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Paclitaxel (Taxol) (paclitaxel)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED